600276 恒瑞医药
已收盘 08-14 15:00:00
资讯
新帖
简况
恒瑞医药两款创新药同日宣布获批临床试验 一季度创新药收入占比超六成
每日经济新闻 · 08-12 18:05
恒瑞医药两款创新药同日宣布获批临床试验 一季度创新药收入占比超六成
恒瑞医药(01276)8月12日斥资679.4万元回购12.5万股A股
智通财经 · 08-12 16:47
恒瑞医药(01276)8月12日斥资679.4万元回购12.5万股A股
恒瑞医药(600276.SH)：多肽类药物HRS-4729注射液获得药物临床试验批准
智通财经 · 08-12 16:41
恒瑞医药(600276.SH)：多肽类药物HRS-4729注射液获得药物临床试验批准
花旗集团在恒瑞医药的H股好仓比例下降0.95%至4.11%
南方财经网 · 08-11 17:21
花旗集团在恒瑞医药的H股好仓比例下降0.95%至4.11%
恒瑞医药又一 NewCo 在美国纳斯达克上市
新浪医药 · 08-10
恒瑞医药又一 NewCo 在美国纳斯达克上市
港股异动 | 剂泰科技-P(07666)早盘涨超16% 自研AiTEM人工智能制剂平台落地恒瑞医药
智通财经 · 08-10
港股异动 | 剂泰科技-P(07666)早盘涨超16% 自研AiTEM人工智能制剂平台落地恒瑞医药
生物制药公司Latigo纳斯达克上市：年亏损1.5亿美元 市值11亿美元 恒瑞医药是股东
雷递 · 08-08
生物制药公司Latigo纳斯达克上市：年亏损1.5亿美元 市值11亿美元 恒瑞医药是股东
恒瑞医药：公司持续通过股票分红等方式回报各位股东
证券日报网 · 08-07
恒瑞医药：公司持续通过股票分红等方式回报各位股东
恒瑞医药：公司以扎实的经营基本面维护公司长期价值，以更好的发展回馈股东
证券日报网 · 08-07
恒瑞医药：公司以扎实的经营基本面维护公司长期价值，以更好的发展回馈股东
恒瑞医药：公司设立员工持股计划方案，旨在建立和完善公司、股东和员工的利益共享机制
证券日报 · 08-07
恒瑞医药：公司设立员工持股计划方案，旨在建立和完善公司、股东和员工的利益共享机制
恒瑞医药：公司致力于发展好主营业务
证券日报网 · 08-07
恒瑞医药：公司致力于发展好主营业务
花旗在江苏恒瑞医药H股的空头头寸从2.36%降至1.39%——港交所数据揭示
美股速递 · 08-07
花旗在江苏恒瑞医药H股的空头头寸从2.36%降至1.39%——港交所数据揭示
港股异动 | 恒瑞医药(01276)尾盘涨超4% 中国首个用于结直肠癌的抗HER2产品获批上市
智通财经 · 08-07
港股异动 | 恒瑞医药(01276)尾盘涨超4% 中国首个用于结直肠癌的抗HER2产品获批上市
生物技术公司Braveheart上市：涨66% 市值21亿美元 恒瑞医药收获IPO
雷递网 · 08-07
生物技术公司Braveheart上市：涨66% 市值21亿美元 恒瑞医药收获IPO
恒瑞医药：注射用曲妥珠单抗瑞泽替康在华获批第三项适应症
美股速递 · 08-06
恒瑞医药：注射用曲妥珠单抗瑞泽替康在华获批第三项适应症
恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗第三项适应症获批上市
智通财经 · 08-06
恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗第三项适应症获批上市
恒瑞医药：子公司注射用瑞康曲妥珠单抗第三项适应症获批上市 成为中国首个获批用于结直肠癌的抗HER2产品
格隆汇 · 08-06
恒瑞医药：子公司注射用瑞康曲妥珠单抗第三项适应症获批上市 成为中国首个获批用于结直肠癌的抗HER2产品
恒瑞医药最新公告：硫酸艾玛昔替尼片获批第五项适应症
证券之星 · 08-06
恒瑞医药最新公告：硫酸艾玛昔替尼片获批第五项适应症
花旗集团在恒瑞医药H股中的多头头寸于7月31日从4.46%攀升至5.06%——港交所披露文件
美股速递 · 08-06
花旗集团在恒瑞医药H股中的多头头寸于7月31日从4.46%攀升至5.06%——港交所披露文件
花旗集团在恒瑞医药的H股好仓比例上升0.60%至5.06%
南方财经网 · 08-06
花旗集团在恒瑞医药的H股好仓比例上升0.60%至5.06%
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.62,"timestamp":1786690800000,"preClose":53.76,"halted":0,"volume":87325060,"delay":0,"changeRate":-0.0212,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":-1.14,"latestTime":"08-14 15:00:00","open":53.68,"high":53.75,"low":52.2,"amount":4615000000,"amplitude":0.0288,"askPrice":52.63,"askSize":576,"bidPrice":52.62,"bidSize":361,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"adjPreClose":53.76,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":59.14,"lowLimit":48.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.49,"roa":"--","peRate":43.014796,"roe":"4.15%","epsLYR":1.19,"committee":0.401789,"marketValue":349249000000,"turnoverRate":0.0137,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.6,"timestamp":1786693038747,"preClose":54.85,"halted":0,"volume":8616186,"delay":0,"premium":"-14.07"},"floatMarketCap":335663000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2658976570","title":"恒瑞医药两款创新药同日宣布获批临床试验 一季度创新药收入占比超六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976570","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658976570?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:05","pubTimestamp":1786529126,"startTime":"0","endTime":"0","summary":"8月11日盘后，恒瑞医药（SH600276，股价54.97元，市值3635.26亿元）连发两则公告，宣布公司及子公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，两款自主研发的创新药获批开展临床试验，研发管线再添新进展。其中一款为针对2型糖尿病的多肽类三靶点激动剂，另一款为针对炎症性肠病的治疗用生物制品，两者在全球范围内均尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839273045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839273045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","LU1655091616.SGD","159992","BMED","LU2097828805.USD","MDTX","LU1064130708.USD","LU2328871848.SGD","LU1580142542.USD","IBBQ","LU2543165471.USD","600276","BK0183","LU2580892789.USD","BK1161","LU2495084118.USD","LU0359201885.HKD","LU0405327494.USD","IBBJ","LU1820825898.SGD","BK1191","LU2148510915.USD","BK0012","PSYK","BK0060","LU1255011170.USD","LU1969619763.USD","LU2097828474.EUR","LU1328615791.USD","MEDX","LU0405327148.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828714.EUR","LU1023057109.AUD","LU1064131003.USD","LNGR","LU1997244956.HKD","LU0359202008.SGD","01276","LU2097828557.USD","LU0359201612.USD","LU2580892862.HKD","BK1574","LU1997245094.SGD","06978","BK0239","BK0196","BK0028","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920076","title":"恒瑞医药(01276)8月12日斥资679.4万元回购12.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658920076?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:47","pubTimestamp":1786524436,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2026年8月12日斥资679.4万元人民币回购12.5万股A股，每股回购价格为54.15-54.41元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU1969619763.USD","LU2097828474.EUR","159982","01276","BK0188","BK0012","LU0359202008.SGD","LU1064131003.USD","LU2495084118.USD","LU2580892789.USD","LU1820825898.SGD","BK0196","LU1781817850.SGD","LU1064130708.USD","LU1997244956.HKD","BK0239","600276","LU2097828557.USD","LU2097828714.EUR","BK0028","LU1580142542.USD","LU1655091616.SGD","399300","LU1328615791.USD","LU2097828805.USD","LU0359201612.USD","LU2289578879.USD","LU2328871848.SGD","BK0060","LU2097828631.EUR","LU1997245177.USD","LU0405327494.USD","LU1997245094.SGD","LU1146622755.USD","LU2580892862.HKD","BK0183","LU0405327148.USD","LU2543165471.USD","LU2488822045.USD","LU1255011170.USD","LU2148510915.USD","BK1191","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920168","title":"恒瑞医药(600276.SH)：多肽类药物HRS-4729注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920168","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658920168?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:41","pubTimestamp":1786524108,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4729注射液的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4729注射液是公司自主研发的多肽类药物，是一种胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体/胰高血糖素受体三激动剂。截至目前，HRS4729注射液相关项目累计研发投入约8,160万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","LU1064131003.USD","LU2097828714.EUR","LU2097828805.USD","BK0060","BK0239","IBBQ","LU0405327148.USD","LU1781817850.SGD","LU2097828631.EUR","LU1328615791.USD","IBBJ","LU2580892789.USD","LU1655091616.SGD","LU2580892862.HKD","LU2543165471.USD","LU2097828474.EUR","MDTX","LU0359201612.USD","PSYK","BK1191","BK0028","LU2097828557.USD","BK0012","LU1255011170.USD","LU2148510915.USD","BK0188","LU1023057109.AUD","BK0183","BK0196","LU1146622755.USD","LU1969619763.USD","01276","LU0359202008.SGD","LU1820825898.SGD","LU1997245177.USD","LU2289578879.USD","LU1064130708.USD","LU2328871848.SGD","LU1580142542.USD","LU0359201885.HKD","LU2488822045.USD","LU1997244956.HKD","BMED","LU1997245094.SGD","LU2495084118.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658996657","title":"花旗集团在恒瑞医药的H股好仓比例下降0.95%至4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658996657","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658996657?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:21","pubTimestamp":1786440099,"startTime":"0","endTime":"0","summary":"南财智讯8月11日电，香港交易所披露信息显示，CitigroupInc.（花旗集团）在恒瑞医药的H股好仓（L）比例于8月3日从5.06%下降至4.11%。同时淡仓（S）比例从2.36%降至1.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837955023.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837955023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU0170899867.USD","LU1064131003.USD","LU0359202008.SGD","LU0072461881.USD","LU0130102774.USD","LU1668664300.SGD","LU2417539215.USD","LU1064130708.USD","LU2236285917.USD","LU1791807156.HKD","LU1366192091.USD","600276","LU0128525689.USD","BK0060","LU1074936037.SGD","BK0028","LU1244550577.SGD","LU1969619763.USD","01276","LU2097828805.USD","BK4534","LU2125154935.USD","LU0405327148.USD","LU0405327494.USD","LU0314106906.USD","LU0980610538.SGD","LU2097828714.EUR","LU2456880835.USD","FTXO","LU1997244956.HKD","BK0012","LU0162691827.USD","LU1201861249.SGD","LU1146622755.USD","TFNS","LU1997245094.SGD","LU0648001328.SGD","LU0203345920.USD","BK4207","IYF","LU1781817850.SGD","LU2462157665.USD","LU2097828474.EUR","LU2580892862.HKD","LU1997245177.USD","BK4588","LU0320765646.SGD","LU2360032135.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658368469","title":"恒瑞医药又一 NewCo 在美国纳斯达克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2658368469","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658368469?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:32","pubTimestamp":1786361520,"startTime":"0","endTime":"0","summary":"8 月 9 日，恒瑞医药宣布其合作伙伴 Braveheart Bio 公司已于当地时间 8 月 6 日成功在美国纳斯达克交易所挂牌上市。这是继 Kailera Therapeutics 之后，恒瑞第二家在美股成功上市的 NewCo 合作公司。2025 年 9 月，恒瑞医药与 Braveheart Bio 达成独家许可协议，将 HRS-1893 的海外开发、生产和商业化的独家权利有偿许可给 Braveheart Bio。根据协议，恒瑞医药获得 3250 万美元现金及 3250 万股 Braveheart Bio 无投票权 A 类优先股的首付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-10/doc-inimvsvm4894441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828805.USD","SG9999014021.USD","LU0405327148.USD","LU1655091616.SGD","LU1328615791.USD","BK0012","600276","LU1969619763.USD","BK0028","LU1580142542.USD","BK0060","BK0183","BK0196","LU1820825898.SGD","LU1997245094.SGD","LU2097828631.EUR","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2328871848.SGD","SG9999014039.USD","LU2580892789.USD","IE00BN0W2T93.GBP","LU2148510915.USD","SG9999014005.SGD","LU2580892862.HKD","LU1064131003.USD","LU2495084118.USD","BK4112","01276","IE00BGHQF748.EUR","LU2097828557.USD","LU2210149790.SGD","LU1781817850.SGD","LU1064130708.USD","LU2289578879.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","BK0239","LU1997244956.HKD","LU1146622755.USD","LU2097828714.EUR","BCDF","LU2095319765.USD","BK0188","LU0405327494.USD","LU1255011170.USD","LU2488822045.USD","LU2097828474.EUR","BK4585","LU0314104364.USD","IE00B64PRP62.GBP","LU1997245177.USD","IE00BKPKM429.USD","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658760987","title":"港股异动 | 剂泰科技-P(07666)早盘涨超16% 自研AiTEM人工智能制剂平台落地恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2658760987","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658760987?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:36","pubTimestamp":1786325777,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P早盘涨超16%，截至发稿，涨15.74%，报12.87港元，成交额1300.47万港元。消息面上，剂泰科技近日公告，公司自主研发的AiTEM人工智能制剂创新平台将在恒瑞医药进行本地化部署，加速药物制剂配方开发效率。据悉，AiTEM曾赋能剂泰科技自研管线MTS-004的剂型开发，将临床前制剂优化周期从行业平均的1-2年缩短至3个月内完成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AIQU","QID","PBOT","SQQQ","TECY","01276","LCLG","VXUS","AIFD","DQJN","ARTY","CWC","AIBU","TQQY","NJUL","GPIQ","161631","MVPS","NBDS","OGIG","QDEC","KCAI","NEWZ","07666","600276","QQQX","QTOC","GK","CHAT","QQQ","WPAI","NOCT","QQQM","QSWN","NAPR","CPNQ","AGIX","TARK","FWD","AQGX","KOMP","QQA","QLD","VUSE","NJAN","MFIG","TQQQ","PSQ","QMAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658344673","title":"生物制药公司Latigo纳斯达克上市：年亏损1.5亿美元 市值11亿美元 恒瑞医药是股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2658344673","media":"雷递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658344673?lang=zh_cn&edition=full","pubTime":"2026-08-08 21:08","pubTimestamp":1786194480,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 8月8日生物制药公司Latigo Biotherapeutics日前在美国纳斯达克上市。Latigo Biotherapeutics发行价为18美元，发行1920万股，募资总额为3.456亿美元。Latigo Biotherapeutics开盘价21美元，较发行价上涨16.7%；收盘价为18.25美元，较发行价上涨1.39%；以收盘价计算，公司市值为11亿美元。年亏损1.5亿美元Latigo Biotherapeutics是一家处于临床阶段的生物制药公司，成立于2018年，由Westlake Village BioPartners孵化，其科学基础源自巴尔的摩Lieber脑发育研究所。Latigo Biotherapeutics致力于开发创新的非阿片类镇痛药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzQ5NjIyMQ==&mid=2661679767&idx=2&sn=5ed2affcdb191c16fc2a8f6e575dc67f&chksm=bc606a6522f55c77915ccc4f883ec12cd1bd5e08afb2aed2a8ec8ab9ef65f78c49049fb5949c&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2097828805.USD","LU0405327148.USD","LU1655091616.SGD","LU1328615791.USD","BK0012","600276","LU1969619763.USD","BK0028","LU1580142542.USD","BK0060","BK0183","BK0196","LU1820825898.SGD","LU1997245094.SGD","LU2097828631.EUR","LU2328871848.SGD","LU2580892789.USD","LU2148510915.USD","LU2580892862.HKD","LU1064131003.USD","LU2495084118.USD","LU2097828557.USD","159632","LU1781817850.SGD","LU1064130708.USD","LU2289578879.USD","BK0239","LU1997244956.HKD","LU1146622755.USD","LU2097828714.EUR","BK0188","LU0405327494.USD","LU1255011170.USD","LU2488822045.USD","LU2097828474.EUR","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657442696","title":"恒瑞医药：公司持续通过股票分红等方式回报各位股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2657442696","media":"证券日报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657442696?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:02","pubTimestamp":1786111320,"startTime":"0","endTime":"0","summary":"证券日报网讯8月7日，恒瑞医药在互动平台回答投资者提问时表示，公司2000年在上海证券交易所上市实际募资约4.67亿元。自2000年A股上市以来，公司持续通过股票分红等方式回报各位股东，目前A股累计现金分红金额约106亿元，远高于公司在A股市场的融资规模。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3049690.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3049690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU2580892789.USD","BK4585","BK4588","LU0405327148.USD","01276","LU1997245094.SGD","LU2097828474.EUR","LU0405327494.USD","LU1146622755.USD","LU2097828805.USD","BK0183","LU1969619763.USD","LU1820825898.SGD","LU1064131003.USD","LU2580892862.HKD","LU0359201885.HKD","LU1655091616.SGD","LU2495084118.USD","BK0239","LU1255011170.USD","BK0028","BK0012","LU1997244956.HKD","BK0060","BK0196","LU1997245177.USD","600276","LU2488822045.USD","LU0359202008.SGD","VIG","LU1580142542.USD","LU0359201612.USD","LU2097828557.USD","BK1191","LU1328615791.USD","LU1023057109.AUD","LU2148510915.USD","LU1781817850.SGD","LU2097828631.EUR","LU2328871848.SGD","LU2289578879.USD","LU2543165471.USD","BK0188","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657064422","title":"恒瑞医药：公司以扎实的经营基本面维护公司长期价值，以更好的发展回馈股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2657064422","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657064422?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:02","pubTimestamp":1786111320,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级证券日报网讯8月7日，恒瑞医药在互动平台回答投资者提问时表示，公司始终坚持科技创新与国际化战略，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。目前本次回购尚未结束，公司将在期限内继续进行回购，并根据进展情况及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3047994.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3047994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1580142542.USD","01276","LU2148510915.USD","LU1969619763.USD","LU1997245177.USD","LU1997245094.SGD","BK0196","LU1781817850.SGD","LU1655091616.SGD","LU2328871848.SGD","LU2097828805.USD","LU2097828557.USD","LU2488822045.USD","BK0188","LU0359201885.HKD","BK1191","LU2580892789.USD","LU0359201612.USD","LU2097828474.EUR","BK0012","LU0405327148.USD","LU1023057109.AUD","LU1146622755.USD","BK0028","LU2580892862.HKD","LU1255011170.USD","LU2097828631.EUR","BK0060","LU1997244956.HKD","LU2289578879.USD","LU2495084118.USD","BK0183","LU2097828714.EUR","LU1064130708.USD","LU1328615791.USD","LU0359202008.SGD","600276","LU2543165471.USD","BK0239","LU1064131003.USD","LU1820825898.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061641","title":"恒瑞医药：公司设立员工持股计划方案，旨在建立和完善公司、股东和员工的利益共享机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061641","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061641?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:42","pubTimestamp":1786110120,"startTime":"0","endTime":"0","summary":"证券日报网讯8月7日，恒瑞医药在互动平台回答投资者提问时表示，公司董事会2025年8月20日审议通过本期回购方案，以自有资金回购公司A股股份，回购的股份拟用于A股员工持股计划，本期回购股票需依据方案规定用途分配。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835509362.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835509362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","LU2097828631.EUR","LU1255011170.USD","BK0060","LU1655091616.SGD","LU1580142542.USD","LU2097828474.EUR","LU2097828805.USD","LU2580892862.HKD","BK0188","BK0196","LU1328615791.USD","LU2328871848.SGD","LU2148510915.USD","LU1023057109.AUD","LU2488822045.USD","LU0405327148.USD","600276","LU2289578879.USD","LU1781817850.SGD","BK0012","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","LU1064130708.USD","BK0028","BK1191","LU1820825898.SGD","LU1997244956.HKD","LU1146622755.USD","BK0239","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU2097828557.USD","LU2495084118.USD","01276","BK0183","LU0359202008.SGD","LU2580892789.USD","LU0405327494.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645830","title":"恒瑞医药：公司致力于发展好主营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645830","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657645830?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:44","pubTimestamp":1786103040,"startTime":"0","endTime":"0","summary":"证券日报网讯8月7日，恒瑞医药在互动平台回答投资者提问时表示，二级市场股价波动受多重因素综合影响，公司严格按照相关规定进行股票回购。公司致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzse9901743.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzse9901743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1328615791.USD","BK0239","LU1781817850.SGD","01276","BK0188","LU1997245177.USD","BK0028","BK0012","600276","LU1580142542.USD","LU1997244956.HKD","LU2097828631.EUR","LU0359202008.SGD","LU2495084118.USD","LU2580892789.USD","LU1997245094.SGD","BK0183","LU1064130708.USD","LU0405327494.USD","LU1023057109.AUD","LU2148510915.USD","BK0060","LU1064131003.USD","LU2488822045.USD","LU2543165471.USD","LU2289578879.USD","LU1255011170.USD","LU2097828805.USD","LU1969619763.USD","LU0405327148.USD","LU2580892862.HKD","BK1191","LU2097828474.EUR","LU2097828714.EUR","LU1820825898.SGD","BK0196","LU2328871848.SGD","LU0359201885.HKD","LU2097828557.USD","LU1655091616.SGD","LU0359201612.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189359312","title":"花旗在江苏恒瑞医药H股的空头头寸从2.36%降至1.39%——港交所数据揭示","url":"https://stock-news.laohu8.com/highlight/detail?id=1189359312","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189359312?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:17","pubTimestamp":1786094279,"startTime":"0","endTime":"0","summary":"据香港交易所数据显示，花旗集团在江苏恒瑞医药H股中的空头头寸，在8月3日已从之前的2.36%显著下降至1.39%。这一变化标志着其持仓策略的重大调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327494.USD","LU2148510915.USD","LU2495084118.USD","LU2097828557.USD","01276","600276","LU1997244956.HKD","LU2097828474.EUR","LU1064130708.USD","LU0359201885.HKD","BK0012","LU2488822045.USD","LU1580142542.USD","BK0183","LU1820825898.SGD","LU0405327148.USD","LU2580892789.USD","LU0359201612.USD","LU0359202008.SGD","LU1997245177.USD","LU1969619763.USD","LU1781817850.SGD","LU2289578879.USD","LU2328871848.SGD","LU2097828714.EUR","LU1146622755.USD","LU1255011170.USD","LU2097828631.EUR","BK0188","LU1655091616.SGD","BK0028","LU1023057109.AUD","BK0239","BK0196","LU2097828805.USD","BK0060","LU1328615791.USD","LU2580892862.HKD","LU1997245094.SGD","LU2543165471.USD","BK1191","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657690773","title":"港股异动 | 恒瑞医药(01276)尾盘涨超4% 中国首个用于结直肠癌的抗HER2产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657690773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657690773?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:20","pubTimestamp":1786087243,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药尾盘涨超4%，截至发稿，涨3.9%，报58.6港元，成交额2.2亿港元。消息面上，8月6日，恒瑞医药公告称，注射用瑞康曲妥珠单抗第三项适应证获批上市，成为中国首个获批用于结直肠癌的抗HER2产品。该适应证用于经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌成人患者。值得注意的是，今年6月，恒瑞医药环孢素滴眼液Ⅳ(恒宜)获上市，用于治疗干眼所致的泪液生成减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LU0405327148.USD","LU2543165471.USD","01276","LU2097828805.USD","600276","LU2097828631.EUR","LU1997245177.USD","LU1064131003.USD","BK1191","LU1328615791.USD","LU2495084118.USD","LU2148510915.USD","IPOS","LU2580892862.HKD","LU1064130708.USD","LU0359201612.USD","BK0012","BK4585","BK4588","BK0060","LU2289578879.USD","LU1580142542.USD","BK0183","LU1969619763.USD","LU1023057109.AUD","LU1146622755.USD","LU1655091616.SGD","LU1255011170.USD","VXUS","LU0405327494.USD","LU2488822045.USD","LU0359202008.SGD","LU1781817850.SGD","BK0028","LU0359201885.HKD","LU2580892789.USD","LU1997245094.SGD","LU1820825898.SGD","BK0239","LU2328871848.SGD","LU2097828557.USD","LU1997244956.HKD","BK0196","KCAI","LU2097828474.EUR","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641596","title":"生物技术公司Braveheart上市：涨66% 市值21亿美元 恒瑞医药收获IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641596","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657641596?lang=zh_cn&edition=full","pubTime":"2026-08-07 07:54","pubTimestamp":1786060487,"startTime":"0","endTime":"0","summary":"美国生物技术公司Braveheart Bio（股票代码：“BRVE”）今日在美国纳斯达克上市。开盘价为30.2美元，收盘价为29.8美元，收盘价较发行价上涨65.56%；以收盘价计算，公司市值为21亿美元。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260807/6392168606822670017644339.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260807/6392168606822670017644339.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34573/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["01276","LU0405327494.USD","LU1023057109.AUD","LU2097828557.USD","FRHC","BK4127","BK0060","LU2488822045.USD","LU0359201612.USD","LU1328615791.USD","LU1997245094.SGD","LU2328871848.SGD","LU1255011170.USD","BK0183","LU2097828474.EUR","LU2580892789.USD","LU2097828805.USD","BK0012","REDS","BK0028","BK0196","LU1969619763.USD","LU1781817850.SGD","LU1655091616.SGD","IPOS","LU2097828631.EUR","LU2543165471.USD","LU1146622755.USD","LU1997244956.HKD","600276","LU2148510915.USD","LU2580892862.HKD","LU1997245177.USD","BK0239","LU2495084118.USD","LU2289578879.USD","LU1064131003.USD","LU0405327148.USD","BK0188","KCE","BK1191","LU1580142542.USD","LU0359201885.HKD","LU0359202008.SGD","LU2097828714.EUR","LU1820825898.SGD","WDNA","HELX","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121188880","title":"恒瑞医药：注射用曲妥珠单抗瑞泽替康在华获批第三项适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188880","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121188880?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:35","pubTimestamp":1786019710,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其核心产品注射用曲妥珠单抗瑞泽替康已获得中国国家药品监督管理局批准，用于治疗特定适应症。这标志着该药物在华获批上市的第三项适应症。根据公告，NMPA的批准是基于该药物在关键临床试验中展现出的显著疗效和可控的安全性数据。恒瑞医药在肿瘤治疗领域持续深耕，此次获批不仅巩固了其在该领域的领先地位，也彰显了公司在抗体偶联药物等前沿技术上的研发实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1146622755.USD","LU2488822045.USD","01276","LU0359201612.USD","LU1064131003.USD","LU2543165471.USD","LU2580892789.USD","BK0060","BK0239","LU2495084118.USD","LU2148510915.USD","LU1997245094.SGD","BK1191","BK0183","600276","BK0028","LU2328871848.SGD","LU1580142542.USD","LU1969619763.USD","LU0405327494.USD","BK0188","LU2097828714.EUR","LU1023057109.AUD","LU1064130708.USD","BK0012","LU0359202008.SGD","LU1655091616.SGD","LU1781817850.SGD","LU1820825898.SGD","LU1255011170.USD","LU0359201885.HKD","LU1328615791.USD","LU2580892862.HKD","LU2097828557.USD","LU2097828631.EUR","LU2097828474.EUR","LU1997245177.USD","LU1997244956.HKD","LU2097828805.USD","BK0196","LU2289578879.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663550","title":"恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗第三项适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663550","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657663550?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:37","pubTimestamp":1786016254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局的通知，公司注射用瑞康曲妥珠单抗第三项适应症获批上市，成为中国首个获批用于结直肠癌的抗HER2产品。批准的适应症：用于经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌成人患者。公司注射用瑞康曲妥珠单抗已在国内获批两项适应症，分别为：用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者;用于治疗既往接受过一种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","LU1146622755.USD","LU2097828714.EUR","LU2097828631.EUR","LU2580892789.USD","LU0359201612.USD","BK0060","LU1997245177.USD","BK0196","BK0012","LU1064131003.USD","LU2488822045.USD","LU2097828805.USD","LU0405327494.USD","LU1580142542.USD","BK1191","LU1255011170.USD","LU0405327148.USD","LU2580892862.HKD","LU1655091616.SGD","LU0359202008.SGD","LU2328871848.SGD","600276","LU1997245094.SGD","BK0183","BK0188","BK0028","BK0239","LU0359201885.HKD","LU1781817850.SGD","LU2495084118.USD","LU1969619763.USD","LU2289578879.USD","LU1064130708.USD","LU1820825898.SGD","LU2148510915.USD","LU1023057109.AUD","IPOS","LU1328615791.USD","LU2543165471.USD","LU2097828557.USD","LU2097828474.EUR","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638885","title":"恒瑞医药：子公司注射用瑞康曲妥珠单抗第三项适应症获批上市 成为中国首个获批用于结直肠癌的抗HER2产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638885","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657638885?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:03","pubTimestamp":1786014213,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1064131003.USD","LU2148510915.USD","LU2289578879.USD","600276","LU0359201612.USD","LU2580892789.USD","LU1328615791.USD","LU2097828631.EUR","LU0359201885.HKD","LU2580892862.HKD","01276","LU2097828805.USD","BK0028","LU0359202008.SGD","BK0183","LU1146622755.USD","LU2097828714.EUR","LU2495084118.USD","LU2328871848.SGD","LU1969619763.USD","LU2097828557.USD","LU0405327494.USD","LU1781817850.SGD","BK0196","LU1997245094.SGD","LU1023057109.AUD","LU0405327148.USD","LU1064130708.USD","LU1997245177.USD","LU2488822045.USD","BK1191","LU1255011170.USD","BK0188","LU1580142542.USD","BK0239","LU2543165471.USD","LU1820825898.SGD","LU1997244956.HKD","LU1655091616.SGD","LU2097828474.EUR","BK0060","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657383446","title":"恒瑞医药最新公告：硫酸艾玛昔替尼片获批第五项适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2657383446","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657383446?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:01","pubTimestamp":1786014115,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276.SH)公告称，公司收到国家药监局通知，批准自主研发的1类创新药硫酸艾玛昔替尼片新增第五项适应症，用于对非甾体抗炎药应答不佳或不耐受且存在客观炎症征象的活动性放射学阴性中轴型脊柱关节炎成人患者。该产品此前已获批强直性脊柱炎、类风湿关节炎、特应性皮炎及斑秃四项适应症，本次获批后实现中轴型脊柱关节炎全疾病谱口服靶向管理覆盖。截至目前，该相关项目累计研发投入约12.35亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600033484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1023057109.AUD","LU1969619763.USD","LU2097828474.EUR","01276","BK0188","BK0012","LU0359202008.SGD","LU1064131003.USD","LU2495084118.USD","LU2580892789.USD","LU1820825898.SGD","BK0196","LU1781817850.SGD","LU1064130708.USD","LU1997244956.HKD","BK0239","600276","LU2097828557.USD","LU2097828714.EUR","BK0028","LU1580142542.USD","LU1655091616.SGD","LU1328615791.USD","LU2097828805.USD","LU0359201612.USD","LU2289578879.USD","LU2328871848.SGD","BK0060","LU2097828631.EUR","LU1997245177.USD","LU0405327494.USD","LU1997245094.SGD","LU1146622755.USD","LU2580892862.HKD","BK0183","LU0405327148.USD","LU2543165471.USD","LU2488822045.USD","LU1255011170.USD","LU2148510915.USD","BK1191","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129374071","title":"花旗集团在恒瑞医药H股中的多头头寸于7月31日从4.46%攀升至5.06%——港交所披露文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1129374071","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129374071?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:31","pubTimestamp":1786012305,"startTime":"0","endTime":"0","summary":"据港交所披露文件显示，花旗集团在恒瑞医药H股中的多头头寸已在7月31日从4.46%显著增加至5.06%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1655091616.SGD","LU1997245094.SGD","LU2543165471.USD","01276","LU0359201885.HKD","LU2328871848.SGD","LU1328615791.USD","LU1781817850.SGD","LU1146622755.USD","LU2580892862.HKD","LU2097828805.USD","LU2495084118.USD","BK0196","LU2488822045.USD","LU2148510915.USD","BK0188","LU0359201612.USD","LU1969619763.USD","LU1023057109.AUD","LU2097828631.EUR","BK0060","LU1997244956.HKD","LU2097828714.EUR","600276","LU1255011170.USD","BK1191","LU1820825898.SGD","LU2097828474.EUR","LU2097828557.USD","BK0028","LU1997245177.USD","LU1064130708.USD","LU1064131003.USD","LU1580142542.USD","BK0183","LU0405327494.USD","BK0012","BK0239","LU2289578879.USD","LU0405327148.USD","LU2580892789.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657818376","title":"花旗集团在恒瑞医药的H股好仓比例上升0.60%至5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657818376","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657818376?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:16","pubTimestamp":1786007760,"startTime":"0","endTime":"0","summary":"南财智讯8月6日电，香港交易所披露信息显示，CitigroupInc.（花旗集团）在恒瑞医药的H股好仓（L）比例于7月31日从4.46%上升至5.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833938335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833938335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK1191","FTXO","LU2328871848.SGD","LU0130102774.USD","BK0028","LU2289578879.USD","LU0162691827.USD","LU0170899867.USD","LU0203347892.USD","LU1064130708.USD","LU2097828557.USD","LU2148510915.USD","LU2495084118.USD","LU2543165471.USD","LU1267930227.SGD","LU2580892862.HKD","LU0130517989.USD","LU0359201885.HKD","LU1244550221.USD","LU1244550577.SGD","LU1997245094.SGD","BK0239","LU1064131003.USD","TFNS","BK0060","600276","LU1580142542.USD","BK4588","LU1162221912.USD","LU0359202008.SGD","LU1506573853.SGD","IYF","LU0310800965.SGD","LU0052756011.USD","LU0980610538.SGD","LU1328615791.USD","01276","LU2488822045.USD","BK4504","LU1074936037.SGD","LU1969619763.USD","LU2360032135.SGD","LU1244550494.USD","LU1655091616.SGD","LU0106831901.USD","LU2456880835.USD","LU0405327494.USD","BK0012","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786693043225,"stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0193},{"period":"3month","weight":-0.0002},{"period":"6month","weight":-0.073},{"period":"1year","weight":-0.1378},{"period":"ytd","weight":-0.0938}],"compareEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.0504},{"period":"6month","weight":-0.038},{"period":"1year","weight":0.0661},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}